🔴 Nuvation Bio is trading 4.1% down today with no clear company-specific catalyst

Nuvation Bio is trading 4.1% down at $6.25 after no clear company-specific catalyst emerged on September 10, 2026.

• A September 9 Citigroup summit discussion highlighted IBTROZI, safusidenib, and the DDC platform; no September 10 press release, earnings update, FDA action, or analyst change was tied to the decline.
• Broader selling followed hotter-than-expected PPI, rising yields, and renewed rate-cut concerns.